Inhibitor Therapeutics (INTI) Stock Chart & Stock Price History $0.04 -0.01 (-20.20%) As of 08/14/2025 03:35 PM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Inhibitor Therapeutics Stock Price Performance The Inhibitor Therapeutics (INTI) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 43.54%, with a year-to-date return of -34.94%. In the past month, the stock has decreased 20.20%, reflecting recent market activity. As of the latest close, Inhibitor Therapeutics traded at $0.04 with a market cap of $6.75 million and volume of 12,000 shares. Five years ago, the stock traded at $0.06, representing a 34.83% decrease over that period. At the time, it had a market cap of $22.42 million and a volume of 1 shares. Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-4.63%1 Month Performance-20.20%3 Month Performance-30.18%Year-To-Date Performance-34.94%1 Year Performance-43.54%5 Year Performance-34.83% INTI Stock Chart for Friday, August, 15, 2025 INTI Chart by TradingView Inhibitor Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/14/2025$0.05$0.04-20.20%$0.04$0.0412,000 shs$6.75 million08/13/2025$0.05$0.05$0.05$0.0511,600 shs$8.46 million08/12/2025$0.04$0.05+19.51%$0.05$0.0511,600 shs$8.46 million08/11/2025$0.04$0.04$0.05$0.0428,650 shs$7.08 million08/08/2025$0.05$0.04-12.77%$0.05$0.0428,650 shs$7.08 million08/07/2025$0.05$0.05-9.44%$0.05$0.044,975 shs$8.11 million08/06/2025$0.05$0.05$0.05$0.055,000 shs$8.96 million08/05/2025$0.05$0.05$0.05$0.055,000 shs$8.96 million08/04/2025$0.05$0.05-0.19%$0.05$0.055,000 shs$8.96 million08/01/2025$0.05$0.05-4.94%$0.05$0.051,138 shs$8.97 million Get the Latest News and Ratings for INTI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/31/2025$0.05$0.05$0.05$0.055 shs$9.44 million07/25/2025$0.05$0.05$0.05$0.0575 shs$9.44 million07/24/2025$0.05$0.05$0.05$0.057,000 shs$9.44 million07/23/2025$0.05$0.05$0.05$0.057,000 shs$9.44 million07/22/2025$0.05$0.05+21.56%$0.05$0.057,000 shs$9.44 million07/21/2025$0.05$0.05-6.25%$0.05$0.0524,000 shs$7.77 million07/18/2025$0.05$0.05$0.05$0.045,080 shs$8.28 million07/17/2025$0.05$0.05-2.04%$0.05$0.045,080 shs$8.28 million07/16/2025$0.05$0.05$0.05$0.05500 shs$8.46 million07/15/2025$0.05$0.05$0.05$0.05500 shs$8.46 million07/14/2025$0.05$0.05-2.00%$0.05$0.05500 shs$8.46 million Related Companies Coeptis Therapeutics Stock Chart Provectus Biopharmaceuticals Stock Chart Shattuck Labs Stock Chart Cognition Therapeutics Stock Chart Mana Capital Acquisition Stock Chart Ovid Therapeutics Stock Chart Enlivex Therapeutics Stock Chart Sol-Gel Technologies Stock Chart Mersana Therapeutics Stock Chart Rani Therapeutics Stock Chart Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:INTI) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access